BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 33128119)

  • 1. Clinical Implications of Pre- and Postoperative Circulating Tumor DNA in Patients with Resected Pancreatic Ductal Adenocarcinoma.
    Yamaguchi T; Uemura K; Murakami Y; Kondo N; Nakagawa N; Okada K; Seo S; Hiyama E; Takahashi S; Sueda T
    Ann Surg Oncol; 2021 Jun; 28(6):3135-3144. PubMed ID: 33128119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer.
    Lee MR; Woo SM; Kim MK; Han SS; Park SJ; Lee WJ; Lee DE; Choi SI; Choi W; Yoon KA; Chun JW; Kim YH; Kong SY
    Cancer Sci; 2024 Apr; 115(4):1283-1295. PubMed ID: 38348576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of preoperative circulating tumor DNA in non-small cell lung cancer: a systematic review and meta-analysis.
    Lu J; Feng Y; Guo K; Sun L; Ruan S; Zhang K
    J Cancer Res Clin Oncol; 2024 Jan; 150(1):25. PubMed ID: 38252173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multianalyte Prognostic Signature Including Circulating Tumor DNA and Circulating Tumor Cells in Patients With Advanced Pancreatic Adenocarcinoma.
    Chapin WJ; Till JE; Hwang WT; Eads JR; Karasic TB; O'Dwyer PJ; Schneider CJ; Teitelbaum UR; Romeo J; Black TA; Christensen TE; Redlinger Tabery C; Anderson A; Slade M; LaRiviere M; Yee SS; Reiss KA; O'Hara MH; Carpenter EL
    JCO Precis Oncol; 2022 Jul; 6():e2200060. PubMed ID: 35939771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective Evaluation of Circulating Tumor DNA using Next Generation Sequencing as a Biomarker during Neoadjuvant Chemotherapy in Localized Pancreatic Cancer.
    Shah D; Wells A; Cox M; Dawravoo K; Abad J; D'Souza A; Suh G; Bayer R; Chaudhry S; Zhang Q; Cristofanilli M; Bentrem D; Chawla A
    Ann Surg; 2024 Jan; ():. PubMed ID: 38258582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bead-Based Isolation of Circulating Tumor DNA from Pancreatic Cancer Patients Enables High Fidelity Next Generation Sequencing.
    Balendran-Braun S; Kieler M; Liebmann-Reindl S; Unseld M; Bianconi D; W Prager G; Streubel B
    Cancer Manag Res; 2021; 13():6249-6261. PubMed ID: 34393517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ctDNA whole exome sequencing in pancreatic ductal adenocarcinoma unveils organ-dependent metastatic mechanisms and identifies actionable alterations in fast progressing patients.
    Huerta M; Martín-Arana J; Gimeno-Valiente F; Carbonell-Asins JA; García-Micó B; Martínez-Castedo B; Robledo-Yagüe F; Camblor DG; Fleitas T; Bartolomé MG; Alfaro-Cervelló C; Garcés-Albir M; Dorcaratto D; Forner EM; Seguí V; Mora-Oliver I; Gambardella V; Roselló S; Sabater L; Roda D; Cervantes A; Tarazona N
    Transl Res; 2024 May; ():. PubMed ID: 38782356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Body Mass Index on Presence of ctDNA and Disease Recurrence after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Analysis from BRE12-158.
    Ballinger TJ; Jiang G; Kassem N; Radovich M; Schneider BP
    Clin Cancer Res; 2021 Feb; 27(4):1195-1199. PubMed ID: 33199491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clonal Architecture of
    Ai X; Cui J; Zhang J; Chen R; Lin W; Xie C; Liu A; Zhang J; Yang W; Hu X; Hu X; Zhao Q; Rao C; Zang YS; Ning R; Li P; Chang L; Yi X; Lu S
    Clin Cancer Res; 2021 Feb; 27(3):704-712. PubMed ID: 33188140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Tumor DNA as a Biomarker for Outcomes Prediction in Colorectal Cancer Patients.
    Petrillo A; Salati M; Trapani D; Ghidini M
    Curr Drug Targets; 2021; 22(9):1010-1020. PubMed ID: 33155906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Putative Origins of Cell-Free DNA in Humans: A Review of Active and Passive Nucleic Acid Release Mechanisms.
    Grabuschnig S; Bronkhorst AJ; Holdenrieder S; Rosales Rodriguez I; Schliep KP; Schwendenwein D; Ungerer V; Sensen CW
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33137955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreatic cancer.
    Hussung S; Akhoundova D; Hipp J; Follo M; Klar RFU; Philipp U; Scherer F; von Bubnoff N; Duyster J; Boerries M; Wittel U; Fritsch RM
    BMC Cancer; 2021 Jan; 21(1):49. PubMed ID: 33430810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-free DNA promoter hypermethylation as a diagnostic marker for pancreatic ductal adenocarcinoma - An external validation study.
    Henriksen SD; Stubbe BE; Madsen PH; Johansen JS; Jensen BV; Hansen CP; Johansen MN; Pedersen IS; Krarup H; Thorlacius-Ussing O
    Pancreatology; 2021 May; ():. PubMed ID: 33994313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parallel Analysis of Pre- and Postoperative Circulating Tumor DNA and Matched Tumor Tissues in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Cohort Study.
    Lee JS; Han Y; Yun WG; Kwon W; Kim H; Jeong H; Seo MS; Park Y; Cho SI; Kim H; Kim JY; Seong MW; Jang JY; Park SS
    Clin Chem; 2022 Dec; 68(12):1509-1518. PubMed ID: 36177751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumour DNA-Based molecular residual disease detection in resectable cancers: a systematic review and meta-analysis.
    Zheng J; Qin C; Wang Q; Tian D; Chen Z
    EBioMedicine; 2024 May; 103():105109. PubMed ID: 38614009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. circulating tumor DNA in the immediate post-operative setting.
    Efthymiou V; Queenan N; Haas M; Naegele S; Goss D; Faden DL
    medRxiv; 2023 Oct; ():. PubMed ID: 37873394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating Cell-Free Nucleic Acids as Biomarkers for Diagnosis and Prognosis of Pancreatic Cancer.
    Marin AM; Sanchuki HBS; Namur GN; Uno M; Zanette DL; Aoki MN
    Biomedicines; 2023 Apr; 11(4):. PubMed ID: 37189687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor DNA: toward evolving the clinical paradigm of pancreatic ductal adenocarcinoma.
    Topham JT; Renouf DJ; Schaeffer DF
    Ther Adv Med Oncol; 2023; 15():17588359231157651. PubMed ID: 36895849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liquid biopsy leads to a paradigm shift in the treatment of pancreatic cancer.
    Watanabe F; Suzuki K; Noda H; Rikiyama T
    World J Gastroenterol; 2022 Dec; 28(46):6478-6496. PubMed ID: 36569270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is Cell-Free DNA Testing in Pancreatic Ductal Adenocarcinoma Ready for Prime Time?
    Sheel A; Addison S; Nuguru SP; Manne A
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.